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Abstract
Diffuse infiltrative lymphocytosis syndrome (DILS) is characterised by a persistent CD8+ lymphocytosis and lymphocytic infiltration 
of various organs. The reported prevalence varies between 0.85 – 3%, and appears to be more common in Africans. Patients with 
DILS tend to have higher CD4+ cell counts and survive longer than those patients without DILS. Most patients present with bilateral 
parotid gland enlargement and features of the Sicca syndrome. Extraglandular involvement is common with the lungs being the 
most common site, followed by peripheral neuropathy and liver involvement. DILS is a benign presentation in most patients with few 
complications. Therapeutic trials are lacking although there are isolated reports of good response to antiretroviral and steroid therapy. 
With the high incidence of HIV in our population it is likely that DILS is under diagnosed probably due to our ignorance of this disease. 
Awareness of its various presentations may bring to light undiscovered patients with DILS.
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Introduction
Diffuse infiltrative lymphocytosis syndrome (DILS) is characterised 
by a persistent CD8+ lymphocytosis and lymphocytic infiltration of 
various organs. It was first reported in 1989 from New York in a cohort 
of 12 patients who were HIV positive with parotid gland enlargement, 
pulmonary insufficiency and lymphadenopathy.1
Demographics
The prevalence in the United States of America (USA) was found to 
be 3% (definitive) and 3.4% (possibly) in an HIV positive outpatient 
population.2 In the largest study to date the prevalence was found 
to be 0.85% in an outpatient population of 4100,3 while in France a 
prevalence of 2.5% was noted in a retrospective study.4 DILS appears 
to be more prevalent in Africa than in the USA.5 In the latter study, 48% 
of HIV positive patients had features of DILS on lymph node biopsy.5 
It is reported to be more common in African Americans (60%) than 
American whites (26%).3,5 The odds ratio for DILS for blacks was found 
to be as high as 2.32 in comparison to other races.3
CD4+  and CD8+ cell count in patients with DILS
Patients with DILS generally present in an early HIV stage, have 
higher CD4+ cell counts (commonly above 200/µl), with fewer 
opportunistic infections1,4,6 and are found to be less advanced in 
their HIV clinical stage with longer survival.2,7  Some authors however 
report that up to 37% of their patients met the Centers for Disease 
Control and Prevention case definition of AIDS.3 There has been no 
published literature on the CD8+ cell counts in patients with DILS. 
Our own experience suggests that most of our patients have CD8+ 
lymphocytosis (counts > 835/µl) and some CD8+ hyperlymphocytosis 
(counts > 1500/µl). Unfortunately this presently cannot be used 
to discriminate between diseases at presentation as 50% of our 
population with HIV have increased CD8+ cell counts and 20% have 
CD8+ hyperlymphocyctosis (Levay unpublished results).
Presentation
The most common clinical presentation is asymptomatic salivary 
gland enlargement, typically bilateral parotid gland involvement,1,3,6,8 
with features of the Sicca syndrome (xerostomia in 82% and 
xerophthalmia 35%) or Sjogren’s-like syndrome.3,9 Unilateral parotid 
gland involvement has been reported although this is a rare finding.9 
Salivary gland involvement typically is associated with cervical 
lymphadenopathy,10,11 while generalised lymphadenopathy occurs 
in 80–100% of patients.4,6 DILS can be differentiated from Sjogren’s 
syndrome by the degree of gland enlargement, high occurrence of 
extraglandular involvement, relative absence of auto antibodies, and 
differing HLA associations.12
The lung is the most common extraglandular site of disease, affecting 
31% of patients in the largest patient group investigated for DILS 
to date.3 Up to 60–71% had biopsy proven lymphocytic interstitial 
pneumonitis in smaller studies.4,6 Lung involvement may clinically and 
radiologically mimic Pneumocystis Jiroveci pneumonia.9 A radiological 
picture of an interstitial disease may also be present.13 Two of our 
patients have been misdiagnosed with pulmonary tuberculosis due to 
the miliary pattern on chest X-rays.
 
Peripheral neuropathy has been reported with DILS9 occurring in 
approximately 20–25% of patients,4,6  although typical lymphocytic 
infiltration in nerves has not been demonstrated in all studies.14 All 
studies and case presentations reported thus far note the presence of 
the Sicca syndrome in all patients.7 The neuropathy presents as either 
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acute or sub-acute, there is always a sensory (painful) component, and 
most (67%) are bilateral.l7 Electrophysiological studies show an axonal 
neuropathy in 80% of patients.7
Other less common presentations include liver involvement, which has 
been reported in up to 23% of patients with DILS,3 and can present 
with the picture of hepatitis.9 Only rarely has it been reported to affect 
the gastrointestinal tract.6,15 A single case of splenomegaly has been 
reported.4 Myositis is a common extra-glandular site of involvement, 
occurring in 26% of patients in one study.3,9 Interstitial nephritis may 
occur, however this is an uncommon finding.9,16,17 A single case of 
bilateral pan-uveitis has also been associated with DILS.18
DILS is mostly associated with HIV, although there are isolated 
case reports of seronegative patients with the syndrome.19 A recent 
study found Ebstein-Barr virus markers in all salivary glands with 
immunohistochemistry which may substantiate a role for this virus 
in DILS.8 The same study found no evidence for a possible role of 
cytomegalovirus, as substantiated by other authors.5,8
Histology
Histology generally shows CD8+ lymphocytic infiltration.5 Infiltration 
of the salivary glands is typically periductal, with associated acinar 
atrophy, ductal ectasia, and mild to moderate fibrosis.8 Ductal 
atypia was found in 96% of 30 patients with DILS in a West African 
Clinical case study 1
Patient with DILS presenting with paratoid gland enlargement 
(Figure 1A) and bilateral pulmonary infiltrates predominantly invol-
ving the lower lung regions (Figure 1B). After two weeks of steroid 
therapy she had a dramatic clinical and radiological response (bot-
tom CXR) (Figure 1C). This patient was initially clinically diagnosed 
with pulmonary tuberculosis at the time of presentation (Figure 1B).
Figure 1A: Parotid gland enlargement
Figure 1B:  Bilateral pulmonary infiltrates predominantly involving the lower 
lung regions.
Figure 1C:  Dramatic radiological response after two weeks of steroid 
therapy.
Clinical case study 2
Patient with DILS presenting with a predominantly interstitial pattern 
involving lower lung lobes (Figure 2A) with an example of chest CT 
findings (interstitial, ground glass pattern) (Figure 2B)
Figure 2A: Bilateral interstitial pattern involving lower lung lobes.
Figure 2B: Chest CT findings with an interstitial, ground glass pattern
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study.5 Neuronal involvement shows a marked angiocentric CD8+ 
infiltrate without mural necrosis with expression of HIV p24 protein in 
macrophages.7
Complications
Complications of DILS are few. The majority of patients are 
asymptomatic apart from the Sicca symptoms. There are isolated 
reports of increased incidence of lymphoma in patients with DILS, 
although these studies contain very few patients.7 The discordance 
between findings and reported symptoms may be a clue to underlying 
DILS.
Treatment
There are no randomised controlled trials that have evaluated therapy 
for DILS. Isolated reports of successful treatment with Zidovudine (6/6 
response) and steroids (5/6) have been noted.7 We have had similar 
findings with our patients. It has been our experience that symptoms 
tend to decrease with the declining CD4 cell counts (patients not on 
antiretroviral therapy). Retrospective analysis of an outpatient clinic for 
HIV positive patients showed there was a significant decrease in the 
prevalence of DILS with the introduction of highly active antiretroviral 
therapy.20   We could not find any reports of DILS presenting as a 
component of immune reconstitution.
Conclusions
Very few reports of DILS have been made from southern Africa. This 
may be due to a lack of knowledge concerning this disease or that in our 
population of patients with HIV, DILS may be an uncommon complication 
or presentation. Our experience at Kalafong Hospital, Pretoria would 
seem to support the latter, where the majority of our patients are African 
blacks with a high HIV incidence. Although our patients have a high 
prevalence of CD8+ lymphocytosis, parotid gland enlargement is an 
uncommon finding in stark contrast to the presence of lymphadenopathy 
in our population. Increasing awareness of this apparently rare 
presentation of HIV may uncover undiagnosed DILS.  
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